The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Suzanne S. Farid, PhD
Advertisement
Senior Lecturer (Associate Professor) at the Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London
Articles by Suzanne S. Farid, PhD
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
5